To report on the FDA approval of insulin icodec-abae (Awiqli) as a once-weekly basal insulin for adults with type 2 diabetes.
Key Findings:
Insulin icodec-abae reduces injections from seven to one per week.
Demonstrated efficacy in reducing HbA1c levels compared to daily basal insulin.
Safety profile consistent with the daily basal insulin class.
Interpretation:
Insulin icodec-abae offers a significant advancement in diabetes management by reducing the frequency of injections, potentially improving adherence to treatment.
Limitations:
The approval is based on trials that may not fully represent all populations with type 2 diabetes.
Long-term safety and efficacy data are still needed.
Conclusion:
Awiqli represents a new option for improving glycemic control in adults with type 2 diabetes, with a US launch anticipated in the second half of 2026.
